Meksiprim tab n / 125mg film about 60 pc

Description

Composition
Active substance:
1 tablet contains emoxypine in terms of 100% substance – 0,125 g
Excipients:
Tablet Core: kaolin – 0.00247 g, sodium carboxymethyl – 0.01258 g microcrystalline cellulose – 0.1135 g Povidone – 0.0134 g talc – 0.0053 g of calcium stearate – 0.00275, the sheath: hypromellose – 0.00495 g, macrogol – 0.00128 g, titanium dioxide – 0.00165 g talc – 0.00037 g
Description:
The tablets are round, biconvex shape, film-coated, white to white with colors kremovatam at break – from white to white with grayish or yellowish tint or Valium.
Product form:
Tablets, film-coated 125 mg. 10 tablets in blisters of PVC film and aluminum foil. 6 the contour of cellular packages together with instructions for use placed in a cardboard box.
Contraindications
Hepatic and / or renal insufficiency, increased individual sensitivity to the drug, infancy, pregnancy, breast-feeding.
Dosage
125 mg
Indications
Anxiety disorders in neurotic and neurosis-like states; vegetative-vascular dystonia; mild cognitive disorders of various origins (for psychoorganic asthenic syndrome and disorders caused by acute and chronic disorders of cerebral circulation, craniocerebral traumas, and neuroinfections intoxication, and senile atrophic processes); memory disorders and intellectual impairment in the elderly; exposure to extreme (stress) factors; alcohol withdrawal syndrome with prevalence of neurosis and vegetative-vascular disorders.
Interaction with other drugs
Meksiprim compatible with psychotropic drugs; It enhances the effect of benzodiazepine anxiolytics, antiparkinsonian and carbamazepine. Reduces the toxic effects of ethanol.
Overdose
Symptoms: sleep disturbance (insomnia, in some cases – drowsiness).
Treatment: as a rule, does not require – the symptoms disappear on their own within a day. In severe cases, insomnia recommended to take 10 mg of nitrazepam, oxazepam 10 mg or 5 mg diazepam.
pharmachologic effect
Pharmacological group:
Anti-oxidant agent.
Pharmacodynamics:
Meksiprim refers to heteroaromatic antioxidants. It has a wide spectrum of pharmacological activities: increases resistance to stress, exhibits anxiolytic effect, muscle relaxant effect is not accompanied by; It possesses nootropic properties, prevents and reduces disorders of learning and memory, resulting in aging and exposure to various pathogens; having anticonvulsant activity; exhibits antihypoxic and antioxidant properties; It improves concentration and performance; It weakens the toxic effect of alcohol.
Preparation improves brain tissue metabolism and blood circulation, improve microcirculation and blood rheology, reduce platelet aggregation. It stabilizes the membrane structure of blood cells (erythrocytes and platelets). It has hypolipidemic effect, reduces total cholesterol and low density lipoproteins.
Meksiprima action mechanism is due to its antioxidant and membrane action. It inhibits lipid peroxidation, increases the activity superoksidoksidazy, increases the ratio of lipid-protein membrane reduces viscosity and increases its fluidity. Modulates the activity of membrane enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase) receptor complexes (benzodiazepine, GABA, acetylcholine) that enhances their ability to bind to ligands, helps to preserve the structural and functional organization of biological membranes, transport of neurotransmitters and improve synaptic transmission. Meksiprim increases in the brain, dopamine. Causes increased activation of compensatory aerobic glycolysis and decreased inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in the content of ATP and creatine phosphate, energosinteziruyuschih activation of mitochondrial functions, stabilization of cell membranes.
Pharmacokinetics:
Meksiprim rapidly absorbed from the gastrointestinal tract with a period poluabsorbtsii 0.08-0.1 hours. The time to reach maximum plasma concentration of 0,46-0,5 hours. Meksiprima size maximum plasma concentration is in the range from 50 to 100 ng / ml.
Meksiprima half-life and mean residence time of the drug in the body are respectively 4.7-5.0 h and 4.9-5.2 h. Meksiprim in the human body is extensively metabolized to form his glyukuronokonyugirovannogo product. On average, 12 hours urine excreted unchanged drug 0.3% and 50% of the administered dose glyukuronokonyugata. The most intense and Meksiprim glyukuronokonyugat excreted within the first 4 hours after ingestion. Indicators excretion Meksiprima and its conjugated metabolites have significant individual variability.
Conditions of supply of pharmacies
On prescription.
side effects
Rarely – nausea, dryness of the oral mucosa, drowsiness, allergic reactions.
special instructions
During the period of treatment must be careful when driving and occupation of other potentially hazardous activities that require high concentration and psychomotor speed reactions.
Storage conditions
In a dry place, protected from light and the reach of children at a temperature not higher than 30 ° C.
Dosing and Administration
Meksiprim appointed interior. Applicable therapeutic dose and duration of treatment is determined by the sensitivity of patients to the drug. Started treatment with a dose of 0.25-0.5 g; average daily dose of 0.25-0.5 g, with a maximum daily – 0.8 The daily dose of drug partitioned into 2-3 doses throughout the day.
To treat patients with anxiety disorders, cardiovascular autonomic dysfunction and cognitive impairment Meksiprim used within 2-6 weeks. When coping with alcohol withdrawal syndrome Meksiprim used within 5-7 days.
Course therapy Meksiprimom end gradually decreasing during 2-3 days dose.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist